Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 3, 2012
"Results from a large, Phase III clinical trial show that combination treatment with bevacizumab (Avastin) and standard chemotherapy in the second line setting in patients with advanced colorectal cancer who have received bevacizumab combination treatment first-line extends overall survival. These findings validate the treatment that many U.S. oncologists already provide, and they will likely alter the standard of care in Europe and elsewhere where use of bevacizumab is generally restricted to either first- or second-line treatment," according to a news release. For related story, visit http://www.oncologypractice.com